Clinical Evaluation of Reusable Soft Contact Lenses

Sponsor
Coopervision, Inc. (Industry)
Overall Status
Not yet recruiting
CT.gov ID
NCT06119191
Collaborator
(none)
72
2
5.6

Study Details

Study Description

Brief Summary

The purpose of this study is to confirm the clinical performance of a novel manufacturing process for comfilcon A contact lenses in habitual wearers.

Condition or Disease Intervention/Treatment Phase
  • Device: Control Lenses (comfilcon A with current process)
  • Device: Test Lenses (comfilcon A with novel process)
N/A

Detailed Description

This will be a prospective, multiple day, double (investigator and subject)-masked, randomized, bilateral re-fit parallel arm study comparing Test lenses against appropriate Control lenses. Participants will be randomized to wear either the Test or Control lenses, and the estimated duration of involvement is 4 months.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
72 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Investigator)
Primary Purpose:
Treatment
Official Title:
Clinical Evaluation of Comfilcon A Contact Lenses
Anticipated Study Start Date :
Nov 13, 2023
Anticipated Primary Completion Date :
Feb 29, 2024
Anticipated Study Completion Date :
Apr 30, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Control Lenses

Participants will wear Control Lenses for 4 weeks

Device: Control Lenses (comfilcon A with current process)
Daily wear lenses for 4 weeks

Experimental: Test Lenses

Participants will wear Test Lenses for 4 weeks

Device: Test Lenses (comfilcon A with novel process)
Daily wear lenses for 4 weeks

Outcome Measures

Primary Outcome Measures

  1. Visual Acuity [4 weeks]

    Monocular distance logMAR visual acuity will be measured at distance 4 meters under high illumination, high contrast conditions

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Have had a self-reported oculo-visual examination in the last year.

  • Are at least 18 years of age and has full legal capacity to give their informed consent.

  • Have read and understood the informed consent letter.

  • Are willing and able to follow instructions and maintain the appointment schedule.

  • Have a contact lens spherical prescription between -0.50 D to -6.00 D (inclusive)

  • Are correctable to a visual acuity of 20/40 or better (in each eye) with their habitual vision correction or 20/20 best-corrected.

  • Have spectacle cylinder of ≤ 0.75 D in both eyes.

  • Is a habitual comfilcon A wearer and worn a comfilcon A lens for at least one month (minimum of 8 hours a day, 5 days per week)

  • Currently employ the use of a peroxide or multipurpose solution cleaning and disinfecting regimen in one of the following brand names:

  • Bausch and Lomb BioTrue Multi-Purpose Solution

  • Bausch and Lomb BioTrue Hydration Plus Multi-Purpose Solution

  • Bausch and Lomb ReNu Advanced Formulation Multi-Purpose Solution

  • Alcon Opti-Free Puremoist with Hydraglyde Multi-Purpose Solution

  • Alcon Opti-Free Replenish Multi-Purpose Solution

  • Alcon Clear Care Plus Hydrogen Peroxide Solution

  • Acuvue RevitaLens Multi-Purpose Solution

  • Have clear corneas and no active ocular disease.

  • Have not worn habitual lenses for at least 12 hours before the baseline/screening examination

  • Are willing to wear the study contact lenses for at least 8 hours per day, 5 days per week

Exclusion Criteria:
  • Have never worn contact lenses before.

  • Are currently wearing daily disposable contact lenses.

  • Have any systemic disease affecting ocular health.

  • Are using any systemic or topical medications that will affect ocular health.

  • Have any ocular pathology or abnormality that would affect the wearing of contact lenses.

  • Have any clinically significant lid or conjunctival abnormalities, active neovascularization or any central corneal scars.

  • Are aphakic.

  • Have undergone corneal refractive surgery.

  • Are participating in any other type of eye related clinical or research study.

  • Require a change in lens power from more than 1 diopter as dictated by over-refraction with their habitual lens prescription.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Coopervision, Inc.

Investigators

  • Principal Investigator: Pete Kollbaum, Indiana University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Coopervision, Inc.
ClinicalTrials.gov Identifier:
NCT06119191
Other Study ID Numbers:
  • CV-23-86
First Posted:
Nov 7, 2023
Last Update Posted:
Nov 7, 2023
Last Verified:
Oct 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
Yes
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 7, 2023